DK1261705T3 - Fremgangsmåder og sammensætninger til screening ved hjælp af difteritoksinkonstruktioner - Google Patents

Fremgangsmåder og sammensætninger til screening ved hjælp af difteritoksinkonstruktioner

Info

Publication number
DK1261705T3
DK1261705T3 DK00993043T DK00993043T DK1261705T3 DK 1261705 T3 DK1261705 T3 DK 1261705T3 DK 00993043 T DK00993043 T DK 00993043T DK 00993043 T DK00993043 T DK 00993043T DK 1261705 T3 DK1261705 T3 DK 1261705T3
Authority
DK
Denmark
Prior art keywords
screening
methods
diphtheria toxin
compositions
toxin constructs
Prior art date
Application number
DK00993043T
Other languages
Danish (da)
English (en)
Inventor
Todd M Kinsella
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1261705T3 publication Critical patent/DK1261705T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00993043T 1999-11-12 2000-11-13 Fremgangsmåder og sammensætninger til screening ved hjælp af difteritoksinkonstruktioner DK1261705T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16518999P 1999-11-12 1999-11-12
PCT/US2000/031232 WO2001034806A2 (fr) 1999-11-12 2000-11-13 Procedes et compositions de depistage au moyen d'edifices de toxine de la diphterie

Publications (1)

Publication Number Publication Date
DK1261705T3 true DK1261705T3 (da) 2009-02-02

Family

ID=22597844

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00993043T DK1261705T3 (da) 1999-11-12 2000-11-13 Fremgangsmåder og sammensætninger til screening ved hjælp af difteritoksinkonstruktioner

Country Status (8)

Country Link
EP (1) EP1261705B1 (fr)
JP (1) JP2003513670A (fr)
AT (1) ATE409227T1 (fr)
AU (1) AU2904401A (fr)
CA (1) CA2396626A1 (fr)
DE (1) DE60040348D1 (fr)
DK (1) DK1261705T3 (fr)
WO (1) WO2001034806A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US7060433B1 (en) * 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
DE60032927T2 (de) * 1999-11-10 2007-11-08 Rigel Pharmaceuticals, Inc., South San Francisco Verfahren and zusammenstellungen, die renilla gfp enthalten
US20030170724A1 (en) 2002-03-08 2003-09-11 Anderson David C. Methods of identifying target polypeptides
AU2003225727A1 (en) * 2002-03-08 2003-09-22 Rigel Pharmaceuticals, Inc. COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME
US7189523B2 (en) 2002-07-16 2007-03-13 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
KR20090075800A (ko) * 2006-09-20 2009-07-09 재단법인 한국파스퇴르연구소 세포에서의 표적 단백질 후보의 발현을 검출 및/또는 정량하는 방법 및 소형 분자 모듈레이터의 표적 단백질을 동정하는 방법
KR101482187B1 (ko) * 2013-01-14 2015-01-14 (주)넥스젠바이오텍 녹색형광단백질―인간상피세포재생인자 융합단백질의 생산을 위한 유전자 컨스트럭트 및 이를 이용한 녹색형광단백질-인간상피세포재생인자 융합단백질의 생산방법
KR101661912B1 (ko) * 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008274A2 (fr) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement

Also Published As

Publication number Publication date
CA2396626A1 (fr) 2001-05-17
JP2003513670A (ja) 2003-04-15
WO2001034806A9 (fr) 2002-07-04
WO2001034806A2 (fr) 2001-05-17
AU2904401A (en) 2001-06-06
EP1261705A2 (fr) 2002-12-04
WO2001034806A3 (fr) 2001-11-29
DE60040348D1 (de) 2008-11-06
EP1261705B1 (fr) 2008-09-24
ATE409227T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
ATE466072T1 (de) Bandscheibe
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
IS2508B (is) Mótefni gegn ED-B hneppinu í fíbrónektíni, smíði þeirra og notkanir
PL1668001T3 (pl) Podstawione heteroarylobenzofuranowe kwasy
ATE500323T1 (de) Subtilisin-variante
BRPI0414599A (pt) pirrol-indóis substituìdos
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
HK1071586A1 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
IL149459A0 (en) Recombinant gelatins
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DK1261705T3 (da) Fremgangsmåder og sammensætninger til screening ved hjælp af difteritoksinkonstruktioner
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
AU2003243381A8 (en) Variants of antithrombin iii
DK1446733T3 (da) Glycosylphosphatidylinositol indeholdende polypeptider
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
DE60101364D1 (de) Strahlteiler zur Reduktion von polarisationsabhängigen Effekten
TW200519206A (en) Methods for producing novel medaka and novel medaka
TW200635952A (en) Specific binding agents of human angiopoietin-2
ES1047228Y (es) Union de la esterilla al marco de las puertas.
DK1090037T3 (da) Divalente antistoffragmenter konjugeret til PEG